Evidence for a common endocannabinoid-related pathomechanism in autism spectrum disorders.
In this issue of Neuron, Földy et al. (2013) report that endocannabinoid-mediated signaling at inhibitory synapses is dysregulated in mouse models of autism-associated Neuroligin-3 mutations. These findings carry implications regarding the pathophysiology of autism spectrum disorders and the development of treatment strategies.